No Data
No Data
Scotiabank Maintains Janux Therapeutics(JANX.US) With Hold Rating, Raises Target Price to $62
TD Cowen Remains a Buy on Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc's Promising Data and Strategic Advancements Earn a Reiterated Buy Rating
Janux Therapeutics 5.32M Share Secondary Priced at $63.00
Janux Therapeutics Plans to Use Proceeds for Clinical Development of Internal Product Pipeline, General Corporate Purposes >JANX
Janux Therapeutics Offering Is Expected to Close Around Dec. 6 >JANX
Clement Lemons : okk
章允量 :
103575541 :
RetireWise : Ho ho ho... Santa Claus is coming to town
Adrianlim90 : 1
View more comments...